Strategies to Manage Antibody Drug Conjugates (ADC) - Related Toxicities in Breast Cancer - Episode 2

ADCs in Breast Cancer: Mechanism of Action, and Components

,

Medical experts discuss the distinct mechanisms and components of different antibody-drug conjugates (ADCs), including the drug, antibody, and linker, and how these components contribute to the mechanisms of ADC-related toxicities.

EP. 1: Overview of Current ADCs in Breast Cancer
Now Viewing
EP. 2: ADCs in Breast Cancer: Mechanism of Action, and Components
EP. 3: Overview of SG-Related Neutropenia Rates in Real-Life Setting and in Clinical Trials
EP. 4: Expert Perspectives on the Management of SG-Related Neutropenia
EP. 5: Navigating SG-related Diarrhea
EP. 6: Expert Insights: SG Adverse Events Management including Alopecia & Nausea
EP. 7: Overview of Cardiotoxicity Risk with T-DXd and Monitoring Strategies along with Anti-Nausea strategies
EP. 8: Clinical Management Considerations: Pneumonitis associated with T-DXd
EP. 9: Expert Perspectives: T-DM1 Adverse Events Overview and Management Strategies
EP. 10: Role of Multidisciplinary Team in the Management of Patients Receiving ADCs in Breast Cancer
EP. 11: Future Perspectives on ADCs in Breast Cancer
EP. 12: Expert Insights: Investigational ADCs Safety Profiles
EP. 13: Key Takeaways and Clinical Practice Pearls in the Treatment of Patients with Breast Cancer Receiving ADCs

Video content above is prompted by the following:

  • What are the different mechanisms between these antibody-drug conjugates (ADCs), as well as the different components that make up these ADCs (ie, drug, antibody, linker)?
  • Please briefly comment on how the different ADC components relate to the mechanism of some of the ADC-related toxicities.